Search
Obecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigational[A265040,A265045] It works by targeting B-cell-specific CD19 surface markers present on malignant B cells. … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING, A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING OAntihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein.
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalBy binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity. … Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma
Synonyms: human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMAMeperidine
go.drugbank.com/drugs/DB00454ApprovedInvestigationalA narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. … Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSinapultide
go.drugbank.com/drugs/DB11332ApprovedWithdrawnThis large disadvantage was overcome with animal-derived surfactant products which contain specific proteins but are limited, but must be derived from animal sources. … [L2506] The product was originally developed by the Scripps Research Institute, then licensed to Windtree Therapeutics.
Tick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigational[A237520] Originally developed by Baxter International Inc., TICOVAC was subsequently acquired by Pfizer Inc. in 2014.[L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050] … Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable.
Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.
Cefonicid
go.drugbank.com/drugs/DB01328ApprovedA second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and sof...
Products: CEFONICID BENEDETTI & COTreprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.
Sodium iodide
go.drugbank.com/drugs/DB11119ApprovedInvestigationalSodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine. … Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology.